methylprednisolone hemisuccinate has been researched along with mometasone furoate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bramanti, P; Galuppo, M; Giacoppo, S; Mazzon, E; Pace, S; Rossi, A; Sautebin, L | 1 |
| Bramanti, P; Giacoppo, S; Libro, R; Mazzon, E | 1 |
2 other study(ies) available for methylprednisolone hemisuccinate and mometasone furoate
| Article | Year |
|---|---|
Use of Mometasone furoate in prolonged treatment of experimental spinal cord injury in mice: A comparative study of three different glucocorticoids.
Topics: Animals; Apoptosis; Cell Line; Dexamethasone; Disease Models, Animal; Glucocorticoids; Inflammation; Male; MAP Kinase Signaling System; Methylprednisolone Hemisuccinate; Mice; Mometasone Furoate; Nitric Oxide Synthase Type II; Poly(ADP-ribose) Polymerases; Spinal Cord; Spinal Cord Injuries | 2015 |
Is the Wnt/β-catenin pathway involved in the anti-inflammatory activity of glucocorticoids in spinal cord injury?
Topics: Animals; Anti-Inflammatory Agents; Body Weight; Catenins; Disease Models, Animal; Glucocorticoids; Interleukin-1beta; Male; Methylprednisolone Hemisuccinate; Mice; Mometasone Furoate; Myelitis; Spinal Cord Injuries; Tumor Necrosis Factor-alpha; Wnt Signaling Pathway | 2016 |